Dab2, a Negative Regulator of DC Immunogenicity, Is an Attractive Molecular Target for DC-based Immunotherapy
OncoImmunology - United States
doi 10.4161/2162402x.2014.984550
Full Text
Open PDFAbstract
Available in full text
Date
January 2, 2015
Authors
Publisher
Informa UK Limited